Retatrutide: Complete Research Guide

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly and Company that represents a significant evolution in metabolic peptide research. It is the world's first triple hormone receptor agonist, simultaneously targeting three key metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCGR).

While Semaglutide acts on a single receptor (GLP-1) and tirzepatide targets two (GIP and GLP-1), Retatrutide adds glucagon receptor activation to the equation. This triple mechanism is theorised to produce synergistic metabolic effects that exceed what dual or single agonists can achieve alone.

Early clinical trial data has generated enormous interest in the research community, with Phase 2 results showing weight reductions of up to 24.2% at 48 weeks, and Phase 3 data demonstrating up to 28.7% at 68 weeks — figures that surpass all previously published data for any anti-obesity compound. Retatrutide is not yet approved by any regulatory body and remains under active clinical investigation.

Retatrutide is a synthetic peptide consisting of 39 amino acids, engineered to activate three distinct G-protein-coupled receptors involved in metabolic regulation. Its code name during development is LY3437943.

The peptide is conjugated to a fatty diacid moiety, which promotes reversible binding to serum albumin. This modification extends its circulating half-life to approximately six days, enabling convenient once-weekly subcutaneous administration — similar to the pharmacokinetic approach used in Semaglutide.

Retatrutide's receptor activation profile is specifically calibrated:

• GIP Receptor (GIPR): Approximately 8.9 times more potent than the endogenous GIP ligand. This is Retatrutide's strongest receptor interaction and contributes to glucose-dependent insulin secretion and improved lipid metabolism.

• GLP-1 Receptor (GLP-1R): Approximately 0.4 times as active as the endogenous GLP-1 ligand. This moderate activation promotes satiety, slows gastric emptying, and enhances insulin secretion — the same mechanism behind Semaglutide's effects.

• Glucagon Receptor (GCGR): Approximately 0.3 times as active as the endogenous glucagon ligand. This is the novel component — glucagon receptor activation increases energy expenditure, promotes hepatic fat oxidation, and enhances thermogenesis.

This tailored potency profile is designed to balance efficacy across all three pathways while managing the safety considerations of each receptor's activation.

Retatrutide's mechanism of action is fundamentally multi-modal, engaging three separate but interconnected metabolic pathways simultaneously.

GLP-1 Receptor Activation — Appetite Suppression and Glycaemic Control: By activating GLP-1 receptors in the hypothalamus and the pancreas, Retatrutide reduces appetite, increases satiety, slows gastric emptying, and stimulates glucose-dependent insulin secretion. This is the same pathway targeted by approved GLP-1 receptor agonists like Semaglutide, and it serves as the foundation for the compound's weight management effects.

GIP Receptor Activation — Metabolic Efficiency: GIP receptor agonism facilitates glucose-dependent insulin secretion through a complementary pathway and plays a role in lipid metabolism. Research suggests that GIP receptor activation may also modulate fat storage and energy balance in adipose tissue, contributing to overall metabolic improvement.

Glucagon Receptor Activation — Energy Expenditure and Fat Burning: This is Retatrutide's distinguishing feature. Glucagon receptor agonism increases hepatic glucose output, promotes fat oxidation in the liver, and enhances overall energy expenditure through thermogenesis. This component is believed to be responsible for the additional weight loss observed beyond what GLP-1 and GIP agonism alone can achieve.

Synergistic Effects: The combined activation of all three receptors produces effects greater than the sum of their individual contributions. The GLP-1 and GIP pathways suppress appetite and improve glycaemic control, while glucagon receptor activation increases the body's caloric expenditure — addressing both sides of the energy balance equation simultaneously.

At the cellular level, receptor binding triggers G-protein coupling, activating adenylate cyclase and increasing intracellular cyclic AMP (cAMP). This secondary messenger activates protein kinase A (PKA) and downstream effectors that modulate gene expression, hormone release, and metabolic activity.

Retatrutide is under active clinical investigation through Eli Lilly's TRIUMPH trial programme. Key research applications include:

• Obesity and Chronic Weight Management: The primary research focus. Phase 2 trials showed mean weight reductions of up to 24.2% at 48 weeks in participants without diabetes. Phase 3 TRIUMPH-4 data demonstrated up to 28.7% weight loss at 68 weeks — the highest figure reported for any anti-obesity compound in a controlled trial. Notably, participants had not reached a weight loss plateau at study end, suggesting even greater reductions may be achievable with longer treatment.

• Type 2 Diabetes Mellitus: Retatrutide is being evaluated for glycaemic control in people with T2DM. Phase 2 data showed clinically significant reductions in HbA1c alongside weight loss.

• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Formerly known as non-alcoholic fatty liver disease (NAFLD). Phase 2 data showed dramatic dose-dependent reductions in liver fat content, ranging from 42.9% to 82.4% reduction at 24 weeks across different doses — a result that has generated particular excitement among hepatology researchers.

• Cardiovascular Risk Reduction: Clinical data shows reductions in non-HDL cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), and systolic blood pressure (up to 14 mmHg reduction with the highest dose).

• Osteoarthritis: The TRIUMPH-4 trial specifically enrolled participants with knee osteoarthritis. Results showed significant reductions in pain scores (up to 75.8%) and improved physical function, with more than 1 in 8 treated patients becoming completely free from knee pain.

• Body Composition: Substudy data demonstrated that Retatrutide significantly reduces total body fat mass (up to 26.1% reduction at 36 weeks) while maintaining a lean-mass-to-weight-loss ratio comparable to other obesity treatments.

Retatrutide is an investigational compound currently available only through clinical trials. No regulatory body has approved dosing guidelines. The following protocols are derived from published clinical trial data and are presented for research reference only.

Phase 2 Trial Doses Studied: • 1 mg once weekly (lowest dose) • 4 mg once weekly • 8 mg once weekly • 12 mg once weekly (highest dose studied)

Dose Escalation: All clinical trials employed a gradual dose-escalation model, increasing the dose incrementally over several weeks to improve tolerability and minimise gastrointestinal side effects. This is consistent with the approach used for other incretin-based therapies including Semaglutide.

Administration: Once-weekly subcutaneous injection. The fatty diacid modification provides a half-life of approximately six days, supporting weekly dosing.

Pharmacokinetics: • Half-life: ~6 days • Time to maximum concentration (Tmax): 12–72 hours post-injection • Pharmacokinetics are dose-proportional • Steady-state reached within approximately 4 weeks of weekly dosing

Phase 3 Doses: The TRIUMPH-4 Phase 3 trial evaluated 9 mg and 12 mg weekly doses. Additional Phase 3 trials are evaluating a 4 mg maintenance dose option.

It is important to note that Retatrutide is not commercially available. It cannot be legally obtained outside of registered clinical trials.

The safety profile of Retatrutide is still being characterised through ongoing clinical trials. Data from Phase 2 and Phase 3 studies indicate a side-effect profile consistent with other incretin-based therapies, with gastrointestinal events being the most commonly reported.

Common Adverse Events (Phase 3 TRIUMPH-4 Data): • Nausea: 38–43% (vs. 11% placebo) • Diarrhoea: 33–35% (vs. 13% placebo) • Constipation: 22–25% (vs. 9% placebo) • Vomiting: 20–21% (vs. 0% placebo) • Decreased appetite: 18–19% (vs. 9% placebo)

These events were generally mild to moderate in severity and most commonly occurred during the dose-escalation phase.

Dysaesthesia: A notable adverse event unique to Retatrutide's profile is dysaesthesia (altered skin sensation), reported in 9–21% of treated patients versus 0.7% with placebo. These events were generally mild and rarely led to treatment discontinuation.

Discontinuation Rates: 12.2% (9 mg group) and 18.2% (12 mg group) discontinued due to adverse events, compared with 4.0% in the placebo group. Some discontinuations were attributed to perceived excessive weight loss.

Theoretical and Long-Term Considerations: • Glucagon receptor agonism could theoretically affect hepatic glucose output, though clinical data has not shown problematic hyperglycaemia • Effects on lean body mass are being monitored, with early data showing acceptable lean-mass preservation • Nutritional deficiencies from sustained appetite suppression and reduced food intake • Long-term cardiovascular and oncological safety data remain pending

Contraindications (Based on Clinical Trial Exclusion Criteria): • History of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 • Active or recent pancreatitis • Pregnancy or breastfeeding • Severe renal or hepatic impairment

Retatrutide is not approved for any use by Health Canada, the U.S. FDA, or any other regulatory agency worldwide. It remains an investigational compound in active clinical development.

The TRIUMPH clinical trial programme, which began in 2023, has enrolled over 5,800 participants across multiple global registrational trials. Seven Phase 3 trials are expected to report results in 2026, evaluating Retatrutide for:

• Chronic weight management (with and without type 2 diabetes)
• Obstructive sleep apnoea
• Knee osteoarthritis
• Cardiovascular and renal outcomes
• Metabolic dysfunction-associated steatotic liver disease (MASLD)

For Canadian researchers, Retatrutide represents a fundamentally different category from research peptides like BPC-157 or TB-500. It is a pharmaceutical-grade compound under corporate development with a clear regulatory pathway, rather than a research chemical available through peptide suppliers.

Retatrutide is not available for purchase through research chemical suppliers. Access is limited to participation in registered clinical trials. Once Phase 3 data is complete and if regulatory submissions are successful, it would become available as a prescription medication in Canada — similar to the pathway Semaglutide followed.

The World Anti-Doping Agency (WADA) has not specifically listed Retatrutide by name, but it would likely fall under the S2 category prohibition on peptide hormones and metabolic modulators, or S4.5 as a metabolic modulator.